세계의 힘줄 동종이식 시장 : 제품 유형별, 최종 사용자별 - 세계 기회 분석과 산업 예측(2023-2032년)

Tendon Allograft Market By Product Type (Achilles Tendon, Tibialis, Patellar Tendon, Others), By End User (Hospitals, Orthopedic Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,862,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,172,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계 힘줄 동종이식 시장은 2022년 264억 8,380만 달러에서 2032년까지 복합 연간 성장률(CAGR) 5.2%로 성장하여, 2032년에는 427억 1,390만 달러에 이를 것으로 예상됩니다.

힘줄 동종이식은 손상되거나 손상된 건을 시체 기증자로부터 얻은 힘줄로 대체하는 수술입니다. 동종이식 힘줄은 보통 멸균 보존된 조직 은행에서 채취됩니다. 이 수술은 무릎과 어깨 인대 재건과 같은 정형외과 수술로 환부 관절의 기능과 안정성을 회복시키는 데 종종 사용됩니다. 힘줄 동종이식 시장은 몇 가지 요인들로부터 최근 몇 년동안 큰 성장을 이루고 있습니다. 힘줄 동종이식은 손상된 힘줄을 수리하거나 대체하기 위해 정형외과 수술에 사용되어 인간 기증자로부터 채취된 이식임베디드니다. 수술 및 기술의 발전으로 힘줄 동종이식 수술은 더 안전하고 효과적이되었습니다. 낮은 침습 수술과 조직 처리 개선으로 인해 합병증의 위험이 줄어들고 환자 결과가 개선되어 외과 의사들 사이에서 채용이 진행되고 있습니다. 스포츠 및 신체 활동 참여가 증가함에 따라 힘줄 손상을 포함한 스포츠 관련 손상도 증가하고 있습니다. 폴리에틸렌 테레프탈레이트(PET) 및 폴리에테르 에테르 케톤(PEEK)과 같은 합성 이식편은 동종이식편을 대체하는 옵션입니다. 이러한 합성 재료는 표준화 된 특성과 질병 감염의 위험을 줄이는 등의 이점을 가지고 있으며, 힘줄 동종이식 시장 점유율에 도전하고 있습니다. 힘줄 동종이식을 이용한 ACL 재건술 및 기타 수술에는 전문적인 수술 기술과 기술이 필요합니다. 수술 결과의 편차와 잠재적인 합병증은 외과의사 및 의료 시설의 채용률에 영향을 줄 수 있습니다.외과의사가 힘줄 동종이식의 성능에 자신감을 가할수록, 그 적응증은 ACL 재건술 뿐만 아니라, 건판 수복술, 견관절 안정화술, 발목이나 손목의 인대 재건술 등 다른 정형외과 수술에 심지어 퍼질 수 있습니다. 이러한 적응 확대는 힘줄 동종이식 시장 규모가 크게 확대될 것으로 전망됩니다. 고령화 사회에서는 근골격계의 손상이나 변형성 관절증 등의 퇴행성 질환이 되기 쉽고, 힘줄 동종이식을 포함한 수술적 개입이 필요할 수 있습니다. 세계적으로 고령화가 진행됨에 따라 정형외과 수술 수요가 증가하고 힘줄 동종이식 시장의 성장을 견인할 가능성이 높습니다. 성장하는 재생 의료 분야는 새로운 힘줄 수리 및 재생 전략 개발에 유망한 기회를 제공합니다. 이 보고서에서 소개하는 주요 기업에는 Aesculap, Lattice Biologics Ltd., MTF Biologics, LifeNet Health, Integra LifeSciences Corporation, RTI Surgical, Tisue Banks International, AlloSource, Arthrex, Zimmer Biomet Holdings Inc. 등이 있습니다. 시장 경쟁에서 우위를 차지하였고, 각사는 제휴나 인수 등의 전략을 구사해 노력을 계속하고 있습니다

관계자를 위한 주요 이점

• 이 보고서는 2022년부터 2032년까지 힘줄 동종이식 시장 분석 시장 부문, 현재 동향, 추정 동향, 역학을 정량적으로 분석하여 힘줄 동종이식 시장의 강력한 기회를 확인합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해관계자가 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급업체의 잠재력을 밝혀줍니다.
• 힘줄 동종이식 시장의 세분화에 대한 자세한 분석은 시장 기회를 결정하는 데 도움이 됩니다.
• 각 지역의 주요 국가는 시장에 대한 수익 공헌도에 따라 매핑됩니다.
• 시장 기업 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 조사 보고서는 지역별 및 세계 힘줄 동종이식 시장 동향, 주요 기업, 시장 부문, 응용 분야 및 시장 성장 전략의 분석을 포함합니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회
• 평균 판매 가격
• 시장 점유율 분석
• 브랜드 점유율 분석
• 무역 데이터 분석
• 제품 소비
• 밸류체인 분석
• 주요 기업의 상세
• 주요 규제 분석
• 특허 상황
• 규제 가이드라인
• 상환 시나리오

제4장 힘줄 동종이식 시장 : 제품 유형별

• 개요
• 아킬레스건
• 경골근 힘줄
• 슬개건
• 기타

제5장 힘줄 동종이식 시장 : 최종 사용자별

• 개요
• 병원
• 정형외과 클리닉
• 기타

제6장 힘줄 동종이식 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타
• 라틴아메리카, 중동, 아프리카
  • 브라질
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 남아프리카
  • 기타

제7장 경쟁 구도

• 소개
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제8장 기업 프로파일

• Aesculap
• Lattice Biologics Ltd.
• MTF Biologics
• LifeNet Health
• Integra LifeSciences Corporation
• RTI Surgical
• Tissue Banks International
• AlloSource
• Arthrex
• Zimmer Biomet Holdings Inc.

BJH

영문 목차

영문목차

The global tendon allograft market is anticipated to reach $42,713.9 million by 2032, growing from $26,483.8 million in 2022 at a CAGR of 5.2% from 2023 to 2032.A tendon allograft is a surgical procedure in which a damaged or injured tendon is replaced with a tendon obtained from a cadaveric donor. The allograft tendon is typically harvested from a tissue bank where it has been preserved through a process of sterilization and storage. This procedure is often used in orthopedic surgeries, such as ligament reconstruction in the knee or shoulder, to restore function and stability to the affected joint.The tendon allograft market has seen significant growth in recent years due to several factors. Tendon allografts are grafts harvested from human donors and used in orthopedic surgeries to repair or replace damaged tendons. Advances in surgical techniques and technologies have made tendon allograft procedures safer and more effective. Minimally invasive procedures and improvements in tissue processing have reduced the risk of complications and improved patient outcomes, driving adoption among surgeons. With the rise in participation in sports and physical activities, there has been a corresponding increase in sports-related injuries, including tendon injuries. Tendon allografts provide an effective solution for repairing damaged tendons in athletes, driving demand in the market.Synthetic grafts, such as those made from materials like polyethylene terephthalate (PET) or polyether ether ketone (PEEK), present alternatives to allografts. These synthetic options may have advantages such as standardized properties and reduced risk of disease transmission, challenging the market share of tendon allografts. ACL reconstruction and other procedures using tendon allografts require specialized surgical skills and techniques. Variability in surgical outcomes and potential complications may affect adoption rates among surgeons and healthcare facilities. These factors are anticipated to restrain the tendon allograft market growth.As surgeons gain confidence in the performance of tendon allografts, the indications for their use may broaden beyond ACL reconstruction to include other orthopedic procedures, such as rotator cuff repair, shoulder stabilization, and ligament reconstructions in the ankle and wrist. This expansion of indications could significantly increase the market size for tendon allografts. The aging population is more prone to musculoskeletal injuries and degenerative conditions, such as osteoarthritis, which may require surgical interventions involving tendon allografts. As the population continues to age globally, there will likely be an increasing demand for orthopedic procedures, driving the growth of the tendon allograft market. The growing field of regenerative medicine offers promising opportunities for the development of novel tendon repair and regeneration strategies. Tendon-derived stem cells, growth factors, and scaffolds could be combined with allografts to enhance tissue healing and regeneration, providing new avenues for product development and market expansion.The key players profiled in this report include Aesculap, Lattice Biologics Ltd., MTF Biologics, LifeNet Health, Integra LifeSciences Corporation, RTI Surgical, Tissue Banks International, AlloSource, Arthrex, and Zimmer Biomet Holdings Inc. The market players are continuously striving to achieve an upper hand in this competitive market using strategies such as collaborations and acquisitions.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tendon allograft market analysis from 2022 to 2032 to identify the prevailing tendon allograft market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the tendon allograft market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global tendon allograft market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
• Analysis of raw material in a product (by %)
• Investment Opportunities
• Supply Chain Analysis & Vendor Margins
• Technology Trend Analysis
• Market share analysis of players by products/segments
• New Product Development/ Product Matrix of Key Players
• Regulatory Guidelines
• Strategic Recommendations
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• SWOT Analysis

Key Market Segments

By Product Type

• Tibialis
• Patellar Tendon
• Others
• Achilles Tendon

By End User

• Hospitals
• Orthopedic Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • United Arab Emirates
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Aesculap
• Lattice Biologics Ltd.
• MTF Biologics
• LifeNet Health
• Integra LifeSciences Corporation
• RTI Surgical
• Tissue Banks International
• AlloSource
• Arthrex
• Zimmer Biomet Holdings Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities
• 3.5. Average Selling Price
• 3.6. Market Share Analysis
• 3.7. Brand Share Analysis
• 3.8. Trade Data Analysis
• 3.9. Product Consumption
• 3.10. Value Chain Analysis
• 3.11. Key Players Details
• 3.12. Key Regulation Analysis
• 3.13. Patent Landscape
• 3.14. Regulatory Guidelines
• 3.15. Reimbursement Scenario

CHAPTER 4: TENDON ALLOGRAFT MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Achilles Tendon
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Tibialis
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Patellar Tendon
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Others
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: TENDON ALLOGRAFT MARKET, BY END USER

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Hospitals
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Orthopedic Clinics
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: TENDON ALLOGRAFT MARKET, BY REGION

• 6.1. Overview
  • 6.1.1. Market size and forecast By Region
• 6.2. North America
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by Product Type
  • 6.2.3. Market size and forecast, by End User
  • 6.2.4. Market size and forecast, by country
    • 6.2.4.1. U.S.
    • 6.2.4.1.1. Market size and forecast, by Product Type
    • 6.2.4.1.2. Market size and forecast, by End User
    • 6.2.4.2. Canada
    • 6.2.4.2.1. Market size and forecast, by Product Type
    • 6.2.4.2.2. Market size and forecast, by End User
    • 6.2.4.3. Mexico
    • 6.2.4.3.1. Market size and forecast, by Product Type
    • 6.2.4.3.2. Market size and forecast, by End User
• 6.3. Europe
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by Product Type
  • 6.3.3. Market size and forecast, by End User
  • 6.3.4. Market size and forecast, by country
    • 6.3.4.1. Germany
    • 6.3.4.1.1. Market size and forecast, by Product Type
    • 6.3.4.1.2. Market size and forecast, by End User
    • 6.3.4.2. UK
    • 6.3.4.2.1. Market size and forecast, by Product Type
    • 6.3.4.2.2. Market size and forecast, by End User
    • 6.3.4.3. France
    • 6.3.4.3.1. Market size and forecast, by Product Type
    • 6.3.4.3.2. Market size and forecast, by End User
    • 6.3.4.4. Spain
    • 6.3.4.4.1. Market size and forecast, by Product Type
    • 6.3.4.4.2. Market size and forecast, by End User
    • 6.3.4.5. Italy
    • 6.3.4.5.1. Market size and forecast, by Product Type
    • 6.3.4.5.2. Market size and forecast, by End User
    • 6.3.4.6. Rest of Europe
    • 6.3.4.6.1. Market size and forecast, by Product Type
    • 6.3.4.6.2. Market size and forecast, by End User
• 6.4. Asia-Pacific
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by Product Type
  • 6.4.3. Market size and forecast, by End User
  • 6.4.4. Market size and forecast, by country
    • 6.4.4.1. China
    • 6.4.4.1.1. Market size and forecast, by Product Type
    • 6.4.4.1.2. Market size and forecast, by End User
    • 6.4.4.2. Japan
    • 6.4.4.2.1. Market size and forecast, by Product Type
    • 6.4.4.2.2. Market size and forecast, by End User
    • 6.4.4.3. India
    • 6.4.4.3.1. Market size and forecast, by Product Type
    • 6.4.4.3.2. Market size and forecast, by End User
    • 6.4.4.4. South Korea
    • 6.4.4.4.1. Market size and forecast, by Product Type
    • 6.4.4.4.2. Market size and forecast, by End User
    • 6.4.4.5. Australia
    • 6.4.4.5.1. Market size and forecast, by Product Type
    • 6.4.4.5.2. Market size and forecast, by End User
    • 6.4.4.6. Rest of Asia-Pacific
    • 6.4.4.6.1. Market size and forecast, by Product Type
    • 6.4.4.6.2. Market size and forecast, by End User
• 6.5. LAMEA
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by Product Type
  • 6.5.3. Market size and forecast, by End User
  • 6.5.4. Market size and forecast, by country
    • 6.5.4.1. Brazil
    • 6.5.4.1.1. Market size and forecast, by Product Type
    • 6.5.4.1.2. Market size and forecast, by End User
    • 6.5.4.2. Saudi Arabia
    • 6.5.4.2.1. Market size and forecast, by Product Type
    • 6.5.4.2.2. Market size and forecast, by End User
    • 6.5.4.3. United Arab Emirates
    • 6.5.4.3.1. Market size and forecast, by Product Type
    • 6.5.4.3.2. Market size and forecast, by End User
    • 6.5.4.4. South Africa
    • 6.5.4.4.1. Market size and forecast, by Product Type
    • 6.5.4.4.2. Market size and forecast, by End User
    • 6.5.4.5. Rest of LAMEA
    • 6.5.4.5.1. Market size and forecast, by Product Type
    • 6.5.4.5.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product mapping of top 10 player
• 7.4. Competitive dashboard
• 7.5. Competitive heatmap
• 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

• 8.1. Aesculap
  • 8.1.1. Company overview
  • 8.1.2. Key executives
  • 8.1.3. Company snapshot
  • 8.1.4. Operating business segments
  • 8.1.5. Product portfolio
  • 8.1.6. Business performance
  • 8.1.7. Key strategic moves and developments
• 8.2. Lattice Biologics Ltd.
  • 8.2.1. Company overview
  • 8.2.2. Key executives
  • 8.2.3. Company snapshot
  • 8.2.4. Operating business segments
  • 8.2.5. Product portfolio
  • 8.2.6. Business performance
  • 8.2.7. Key strategic moves and developments
• 8.3. MTF Biologics
  • 8.3.1. Company overview
  • 8.3.2. Key executives
  • 8.3.3. Company snapshot
  • 8.3.4. Operating business segments
  • 8.3.5. Product portfolio
  • 8.3.6. Business performance
  • 8.3.7. Key strategic moves and developments
• 8.4. LifeNet Health
  • 8.4.1. Company overview
  • 8.4.2. Key executives
  • 8.4.3. Company snapshot
  • 8.4.4. Operating business segments
  • 8.4.5. Product portfolio
  • 8.4.6. Business performance
  • 8.4.7. Key strategic moves and developments
• 8.5. Integra LifeSciences Corporation
  • 8.5.1. Company overview
  • 8.5.2. Key executives
  • 8.5.3. Company snapshot
  • 8.5.4. Operating business segments
  • 8.5.5. Product portfolio
  • 8.5.6. Business performance
  • 8.5.7. Key strategic moves and developments
• 8.6. RTI Surgical
  • 8.6.1. Company overview
  • 8.6.2. Key executives
  • 8.6.3. Company snapshot
  • 8.6.4. Operating business segments
  • 8.6.5. Product portfolio
  • 8.6.6. Business performance
  • 8.6.7. Key strategic moves and developments
• 8.7. Tissue Banks International
  • 8.7.1. Company overview
  • 8.7.2. Key executives
  • 8.7.3. Company snapshot
  • 8.7.4. Operating business segments
  • 8.7.5. Product portfolio
  • 8.7.6. Business performance
  • 8.7.7. Key strategic moves and developments
• 8.8. AlloSource
  • 8.8.1. Company overview
  • 8.8.2. Key executives
  • 8.8.3. Company snapshot
  • 8.8.4. Operating business segments
  • 8.8.5. Product portfolio
  • 8.8.6. Business performance
  • 8.8.7. Key strategic moves and developments
• 8.9. Arthrex
  • 8.9.1. Company overview
  • 8.9.2. Key executives
  • 8.9.3. Company snapshot
  • 8.9.4. Operating business segments
  • 8.9.5. Product portfolio
  • 8.9.6. Business performance
  • 8.9.7. Key strategic moves and developments
• 8.10. Zimmer Biomet Holdings Inc.
  • 8.10.1. Company overview
  • 8.10.2. Key executives
  • 8.10.3. Company snapshot
  • 8.10.4. Operating business segments
  • 8.10.5. Product portfolio
  • 8.10.6. Business performance
  • 8.10.7. Key strategic moves and developments

관련자료